Risk Factors for Post-ERCP Pancreatitis in High-Risk Patients Receiving Post-procedure Rectal Indomethacin

被引:12
|
作者
Kang, Xiaoyu [1 ]
Zheng, Liyue [1 ]
Zeng, Wei [2 ,3 ]
Yang, Shengye [1 ]
Sun, Hao [4 ]
Zhang, Rongchun [1 ]
Wang, Xiangping [1 ]
Wang, Biaoluo [1 ]
Tao, Qin [1 ]
Yao, Shaowei [1 ]
Chen, Jie [1 ]
Pan, Yanglin [1 ]
Guo, Xuegang [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China
[2] Chinese PLA 174 Hosp, Dept Gastroenterol, Xiamen, Fujian, Peoples R China
[3] Xiamen Univ, Chenggong Hosp, Dept Gastroenterol, Xiamen, Fujian, Peoples R China
[4] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
ERCP; Post-ERCP pancreatitis; Indomethacin; Risk factors; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STENT PLACEMENT; CANNULATION; COMPLICATIONS; METAANALYSIS; PREVENTION; REDUCE; MANAGEMENT; EFFICACY;
D O I
10.1007/s11605-018-3864-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Post-ERCP pancreatitis (PEP) is the most common adverse event of ERCP. Rectal indomethacin has been widely administered to decrease the incidence of PEP in high-risk patients. However, it cannot completely prevent the occurrence of PEP. The purpose of the study was to evaluate the risk factors for PEP in high-risk patients receiving post-ERCP indomethacin. Methods From June 2012 to July 2015, patients undergoing ERCP and at high risk for PEP in three tertiary hospitals in China were enrolled. All patients received indomethacin after the procedure. Patient-related and procedure-related risk factors for PEP were collected. Logistic regression analysis was used to investigate the risk factors. Results Seven hundred ninety patients at high risk for PEP received post-ERCP indomethacin. The incidence of overall PEP and moderate-to-severe PEP was 8.0 and 1.5%, respectively. In multivariate analysis, suspected sphincter of Oddi dysfunction (SOD) (OR 2.73; 95%CI 1.38-5.43; p=0.004), the presence of hilar obstruction (OR 4.53; 95%CI 1.60-12.81; p=0.004), number of cannulation attempts 13 (OR 2.00; 95%CI 1.07-3.77; p=0.030), inadvertent pancreatic duct (PD) cannulation 1 (OR 2.26; 95%CI 1.04-4.90; p=0.040), and pancreatic contrast injections 1 (OR 2.30; 95%CI 1.02-5.23; p=0.046) were high risk factors for overall PEP. For moderate-to-severe PEP, suspected SOD (OR 4.67; 1.19-18.35; p=0.027), the presence of hilar obstruction (OR 7.95; 1.39-44.97; p=0.010), and more cannulation attempts (OR 3.71; 1.09-12.65; p=0.036) were three independent risk factors. Conclusions A substantial number of high-risk patients had PEP even receiving post-ERCP rectal indomethacin. The independent risk factors included suspected SOD, hilar stricture, more cannulation attempts, inadvertent PD cannulation, and PD contrast injections.
引用
收藏
页码:1903 / 1910
页数:8
相关论文
共 50 条
  • [41] A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
    Elmunzer, B. Joseph
    Scheiman, James M.
    Lehman, Glen A.
    Chak, Amitabh
    Mosler, Patrick
    Higgins, Peter D. R.
    Hayward, Rodney A.
    Romagnuolo, Joseph
    Elta, Grace H.
    Sherman, Stuart
    Waljee, Akbar K.
    Repaka, Aparna
    Atkinson, Matthew R.
    Cote, Gregory A.
    Kwon, Richard S.
    McHenry, Lee
    Piraka, Cyrus R.
    Wamsteker, Erik J.
    Watkins, James L.
    Korsnes, Sheryl J.
    Schmidt, Suzette E.
    Turner, Sarah M.
    Nicholson, Sylvia
    Fogel, Evan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15): : 1414 - 1422
  • [42] RECTAL INDOMETHACIN DECREASE THE RISK OF POST-ERCP PANCREATITIS IN CONSECUTIVE PATIENTS. A TERTIARY REFERRAL CENTER EXPERIENCE
    Abdelfatah, Mohamed M.
    Koutlas, Nicholas
    Gochanour, Eric
    Hamed, Ahmad
    Othman, Mohamed O.
    GASTROINTESTINAL ENDOSCOPY, 2018, 87 (06) : AB584 - AB584
  • [43] Risk Factors for Post-ERCP Pancreatitis in Pediatric and Young Adult Patients
    Hassan, Ahmad M.
    Lin, Tom K.
    Smith, Milton T.
    Hornung, Lindsey
    Abu-El-Haija, Maisam
    Nathan, Jaimie D.
    Vitale, David S.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 76 (06): : 807 - 812
  • [44] Lowering the risk of post-ERCP pancreatitis
    Thiruvengadam, Nikhil R.
    Forde, Kimberly A.
    Chandrasekhara, Vinay
    Kochman, Michael L.
    GASTROINTESTINAL ENDOSCOPY, 2017, 85 (03) : 688 - 689
  • [45] Indomethacin as prophylaxis for post-ERCP pancreatitis
    Arlt A.
    Der Gastroenterologe, 2016, 11 (4): : 317 - 318
  • [46] Preventative effects of ulinastatin on post-ERCP pancreatitis in high risk patients
    Yoo, Ji Won
    Ryu, Ji Kon
    Woo, Sang Myung
    Lee, Sang Hyub
    Park, Joo Kyung
    Yoon, Won Jae
    Lee, Jun Kyu
    Lee, Kwang Hyuck
    Hwang, Jin-Hyeok
    Kim, Yong-Tae
    Yoon, Yong Bum
    GASTROINTESTINAL ENDOSCOPY, 2007, 65 (05) : AB241 - AB241
  • [47] Low-dose rectal diclofenac does not prevent post-ERCP pancreatitis in low- or high-risk patients
    Katoh, Takao
    Kawashima, Kousaku
    Fukuba, Nobuhiko
    Masuda, Shigeto
    Kobatake, Hiroko
    Masaki, Kosaku
    Araki, Yasuhiro
    Kawano, Koichiro
    Nishi, Katsuhisa
    Takenaka, Mamoru
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (07) : 1247 - 1253
  • [48] EFFICACY OF PROPHYLACTIC USE OF LOW-DOSE INDOMETHACIN IN REDUCING POST-ERCP PANCREATITIS IN HIGH-RISK POPULATION
    Yalikong, Ayimukedisi
    Qi, Zhipeng
    Chen, Zhanghan
    He, Dongli
    Zhou, Pinghong
    Zhong, Yunshi
    GASTROINTESTINAL ENDOSCOPY, 2023, 97 (06) : AB621 - AB622
  • [49] Assessing the risk factors for post-ERCP pancreatitis and procedure abandonment at a single centre in the UK
    Carey, Charles
    Jaunoo, Shameen
    BRITISH JOURNAL OF SURGERY, 2024, 111
  • [50] POST-ERCP PANCREATITIS - IS THERE INCREASED RISK AT REPEAT ERCP
    HOWERTON, DH
    GEENEN, JE
    HOGAN, WJ
    GASTROINTESTINAL ENDOSCOPY, 1993, 39 (02) : 315 - 315